The Board of Directors of Guerbet, convened on January 28, 2026, upon the recommendation of the Nominations and Compensation Committee, decided to appoint Karim Boussebaa as the CEO of the group. The appointment will be effective from February 2, 2026. Karim Boussebaa is a graduate from the National School of Advanced Sciences and Technologies and holds an MBA from Westminster College (Salt Lake City, USA). He has over 25 years of international experience in the health and medical technology sectors, having previously held leadership positions in leading groups in the fields of medical imaging and medical devices.
Previous Interim CEO
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Jérôme Estampes, who served as the interim CEO, will resume his role as Director of Group Financial Affairs and SVP of Business Development and Licenses starting February 2, 2026.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux / imagerie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 379,2 millions d'euros
Quarterly revenue: 379,2 millions d'euros
Revenue growth: -2,2 %
Guidance from the release
Objectifs financiers intégrant l'impact significatif de la situation du site de Raleigh, Free Cash-Flow fortement négatif
Risks mentioned
Non-respect anticipé du ratio d'endettement net/EBITDA de 3,5x testé au 30 juin 2026
Refinancement à négocier avec les partenaires financiers d'ici au 31 octobre 2026
Free Cash-Flow 2026 attendu fortement négatif entre -50 M€ et -70 M€
Opportunities identified
Normalisation complète attendue du site de Raleigh d'ici fin 2026
Forte croissance en France (+9,0 %) après absorption de la réforme de l'approvisionnement
Radiologie Interventionnelle en hausse de 4,7 % portée par le Lipiodol
Outlook / guidance
Expected EBITDA: 62,9 millions d'euros
Management commentary: Chiffre d'affaires entre stable et en légère décroissance à TCC et périmètre comparable ; Taux de marge d'EBITDA retraité 3 de l'ordre de 8%, incluant environ 35 M€ liés aux coûts du plan de remise en conformité sur le site de Raleigh ; Free Cash-Flow compris entre -50 M€ et -70 M€
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
